CD19 and systemic lupus erythematosus: As B cell-targeted monoclonal antibodies proved therapeutically successful, targeting the B lymphocyte with CD-19-targeted CAR-T cells has been a promising approach for the treatment of SLE patients refractory to standard treatment.